Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Welcome
Go
Free Newsletter Sign Up

Compass Pathways’ New Patents on Psilocybin Challenged in U.S.

Dec. 28, 2021, 6:53 PM

Freedom to Operate, a non-profit that says it’s dedicated to “protecting psychedelic science & medical development for public benefit,” filed petitions with the U.S. Patent and Trademark Office to cancel two new Compass Pathways patents issued in March on psilocybin, the active ingredient in magic mushrooms.

  • Compass Pathways patents 10,947,257 and 10,954,259 shouldn’t have been issued, Freedom to Operate argued in two petitions filed with the Patent Trial and Appeal Board
    • In its petitions, the group launches a raft of arguments for each of the patents -- that they don’t “disclose any novel polymorphic forms of psilocybin” ...



To read the full article log in.

Learn more about a Bloomberg Law subscription.